Compare
Elanco Animal Health Inc vs Perrigo Co PLC vs BeOne Medicines Ltd. vs Alnylam Pharmaceuticals, Inc.
| Latest fiscal year | Elanco Animal Health Inc ELAN | Perrigo Co PLC PRGO | BeOne Medicines Ltd. ONC | Alnylam Pharmaceuticals, Inc. ALNY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.71B | $4.25B | $5.34B | $3.71B |
| Revenue growth (YoY) | +6.2% | -2.8% | +40.2% | +65.2% |
| Gross margin | 55.0% | 35.1% | 87.5% | 81.8% (computed) |
| Operating margin | n/a | -26.4% | 8.4% | 13.5% |
| Net margin | -4.9% | -33.5% | 5.4% | 8.4% |
| Net income | -$232.00M | -$1.43B | $286.93M | $313.75M |
| EPS (Diluted) | -$0.47 | -$10.29 | $0.19 | $2.33 |
| Operating cash flow | $560.00M | $238.50M | $1.13B | $524.08M |
| Free cash flow | $284.00M | $145.10M | $941.74M | $465.38M |
| Cash & equivalents | $545.00M | n/a | $4.55B | $1.66B |
| Total assets | $13.36B | $8.54B | $8.19B | $4.97B |
| Total liabilities | $6.81B | $5.60B | $3.83B | $4.18B |
| Shareholders' equity | $6.55B | $2.94B | $4.36B | $789.18M |
| Return on year-end equity | -3.5% | -48.6% | 6.6% | 39.8% |
| Shares outstanding | 496.98M | 137.60M | 1.44B | 132.38M |
Revenue, most recent five fiscal years
| Fiscal year | Elanco Animal Health Inc | Perrigo Co PLC | BeOne Medicines Ltd. | Alnylam Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $4.71B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $5.34B Ended 2025-12-31 | $3.71B Ended 2025-12-31 |
| 1 year earlier | $4.44B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $3.81B Ended 2024-12-31 | $2.25B Ended 2024-12-31 |
| 2 years earlier | $4.42B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $2.46B Ended 2023-12-31 | $1.83B Ended 2023-12-31 |
| 3 years earlier | $4.41B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $1.42B Ended 2022-12-31 | $1.04B Ended 2022-12-31 |
| 4 years earlier | $4.76B Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $1.18B Ended 2021-12-31 | $844.29M Ended 2021-12-31 |